RU2010131189A - Химически модифицированный фактор iх - Google Patents
Химически модифицированный фактор iх Download PDFInfo
- Publication number
- RU2010131189A RU2010131189A RU2010131189/10A RU2010131189A RU2010131189A RU 2010131189 A RU2010131189 A RU 2010131189A RU 2010131189/10 A RU2010131189/10 A RU 2010131189/10A RU 2010131189 A RU2010131189 A RU 2010131189A RU 2010131189 A RU2010131189 A RU 2010131189A
- Authority
- RU
- Russia
- Prior art keywords
- fix
- hydrophilic polymer
- ser
- soluble hydrophilic
- thr
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title claims abstract 65
- 108010076282 Factor IX Proteins 0.000 claims abstract 71
- 102100022641 Coagulation factor IX Human genes 0.000 claims abstract 69
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract 23
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims abstract 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 9
- 229940050526 hydroxyethylstarch Drugs 0.000 claims abstract 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 8
- 230000004913 activation Effects 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 4
- 229920002307 Dextran Polymers 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 230000007062 hydrolysis Effects 0.000 claims abstract 3
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 229920000642 polymer Polymers 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US926307P | 2007-12-27 | 2007-12-27 | |
| US61/009,263 | 2007-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010131189A true RU2010131189A (ru) | 2012-02-10 |
Family
ID=40344940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010131189/10A RU2010131189A (ru) | 2007-12-27 | 2008-12-19 | Химически модифицированный фактор iх |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090176708A1 (enExample) |
| EP (4) | EP2568043A1 (enExample) |
| JP (1) | JP2011507919A (enExample) |
| KR (1) | KR20100110799A (enExample) |
| CN (1) | CN101952422A (enExample) |
| AU (1) | AU2008342260B2 (enExample) |
| CA (1) | CA2709960A1 (enExample) |
| IL (1) | IL206095A0 (enExample) |
| NZ (3) | NZ603997A (enExample) |
| RU (1) | RU2010131189A (enExample) |
| WO (1) | WO2009083187A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2353588B1 (en) | 2010-01-21 | 2015-04-15 | Agricultural Technology Research Institute | A sustained release preparation of factor IX |
| TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
| US10772942B2 (en) | 2014-03-24 | 2020-09-15 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
| US20220378840A1 (en) * | 2019-11-29 | 2022-12-01 | Rutgers, The State University Of New Jersey | Compositions, kits and methods for storage of blood products and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS538750B2 (enExample) | 1971-08-18 | 1978-03-31 | ||
| AT348548B (de) | 1977-04-08 | 1979-02-26 | Laevosan Gmbh & Co Kg | Verfahren zur herstellung von alsblutplasma- expander geeignerter hydroxyaethylstaerke |
| US5614500A (en) | 1983-03-04 | 1997-03-25 | The Scripps Research Institute | Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography |
| DE3313600A1 (de) * | 1983-04-14 | 1984-10-18 | Laevosan-Gesellschaft mbH & Co. KG, Linz | Plasmastreckmittel auf staerkebasis und verfahren zu ihrer herstellung |
| DE19975071I2 (de) | 1989-06-16 | 2000-02-03 | Fresenius Ag | Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel |
| FR2702160B1 (fr) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
| DE4310974C2 (de) * | 1993-04-03 | 1996-08-01 | Fresenius Ag | Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation |
| FR2704145B1 (fr) | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| EP0973544B1 (de) * | 1997-04-08 | 2001-06-27 | Baxter Aktiengesellschaft | Immuntolerante prothrombinkomplex-präparation |
| US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| EP1694315A4 (en) * | 2003-12-03 | 2009-10-28 | Novo Nordisk As | FACTOR IX GLYCOPEGYL |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| KR101215226B1 (ko) | 2004-03-01 | 2012-12-26 | 베. 브라운 멜중엔 악티엔게젤샤프트 | 하이드록시에틸전분 |
| WO2005092928A1 (en) * | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| WO2006018204A1 (en) * | 2004-08-17 | 2006-02-23 | Zlb Behring Gmbh | Modified vitamin k dependent polypeptides |
| JP2008532966A (ja) * | 2005-03-11 | 2008-08-21 | フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 不活性出発物質からの生理活性糖タンパク質の生成 |
| WO2007101681A1 (en) | 2006-03-07 | 2007-09-13 | Baxter International Inc | Highly phosphorylated and sulfated recombinant factor ix |
| CN101454267B (zh) | 2006-03-29 | 2012-09-26 | 帝斯曼知识产权资产管理有限公司 | 姜黄素的合成 |
| TW200804416A (en) * | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
| EP2155865B1 (en) * | 2007-06-15 | 2014-09-17 | National Research Council Of Canada | Engineered versions of polysialyltransferases with enhanced enzymatic properties |
-
2008
- 2008-12-19 NZ NZ603997A patent/NZ603997A/xx not_active IP Right Cessation
- 2008-12-19 EP EP12008216A patent/EP2568043A1/en not_active Withdrawn
- 2008-12-19 EP EP12008214A patent/EP2568041A1/en not_active Withdrawn
- 2008-12-19 CA CA2709960A patent/CA2709960A1/en not_active Abandoned
- 2008-12-19 NZ NZ598193A patent/NZ598193A/xx not_active IP Right Cessation
- 2008-12-19 CN CN2008801232530A patent/CN101952422A/zh active Pending
- 2008-12-19 RU RU2010131189/10A patent/RU2010131189A/ru not_active Application Discontinuation
- 2008-12-19 EP EP12008215A patent/EP2568042A1/en not_active Withdrawn
- 2008-12-19 EP EP08868384A patent/EP2247723A1/en not_active Withdrawn
- 2008-12-19 US US12/339,619 patent/US20090176708A1/en not_active Abandoned
- 2008-12-19 KR KR1020107014071A patent/KR20100110799A/ko not_active Ceased
- 2008-12-19 NZ NZ585835A patent/NZ585835A/en not_active IP Right Cessation
- 2008-12-19 AU AU2008342260A patent/AU2008342260B2/en not_active Expired - Fee Related
- 2008-12-19 WO PCT/EP2008/010925 patent/WO2009083187A1/en not_active Ceased
- 2008-12-19 JP JP2010540056A patent/JP2011507919A/ja active Pending
-
2010
- 2010-05-31 IL IL206095A patent/IL206095A0/en unknown
-
2011
- 2011-12-29 US US13/339,823 patent/US20120177625A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008342260A1 (en) | 2009-07-09 |
| EP2247723A1 (en) | 2010-11-10 |
| CN101952422A (zh) | 2011-01-19 |
| US20090176708A1 (en) | 2009-07-09 |
| NZ598193A (en) | 2012-12-21 |
| CA2709960A1 (en) | 2009-07-09 |
| JP2011507919A (ja) | 2011-03-10 |
| US20120177625A1 (en) | 2012-07-12 |
| AU2008342260B2 (en) | 2013-10-17 |
| NZ585835A (en) | 2012-07-27 |
| NZ603997A (en) | 2013-02-22 |
| EP2568043A1 (en) | 2013-03-13 |
| EP2568042A1 (en) | 2013-03-13 |
| IL206095A0 (en) | 2010-11-30 |
| KR20100110799A (ko) | 2010-10-13 |
| EP2568041A1 (en) | 2013-03-13 |
| WO2009083187A8 (en) | 2009-09-17 |
| WO2009083187A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8076294B2 (en) | Collagen-related peptides and uses thereof | |
| RU2635510C2 (ru) | Прокоагулянтные пептиды, их производные и их применение | |
| JP2795749B2 (ja) | 高分子薬物の粘膜透過による投与 | |
| EP2459226B1 (en) | Glycopolysialylation of proteins other than blood coagulation proteins | |
| BRPI0612536A2 (pt) | grupo alifático de ligação de pró-fármaco | |
| CN105916524B (zh) | 包含纤维蛋白原结合肽的肽类树状聚合物 | |
| JP2012126750A5 (enExample) | ||
| JP2008525491A5 (enExample) | ||
| US20100021527A1 (en) | Collagen-related peptides and uses thereof and hemostatic foam substrates | |
| BR122019000248B1 (pt) | reagente de ligador de pró-fármaco de cascata polimérico | |
| PT99007A (pt) | Processo para a preparacao de uma composicao farmaceutica nasal que compreende hormona paratiroideia humana (hpth) ou um seu fragmento terminal em n | |
| RU2010131189A (ru) | Химически модифицированный фактор iх | |
| US20200345850A1 (en) | Orally Active, Cell-Penetrating Homing Peptide and Methods Using Same | |
| WO2019061561A1 (zh) | 一种药物递送体系及其制备方法与应用 | |
| US20050282747A1 (en) | Methods and compositions for wound healing | |
| JPH06228199A (ja) | 血液脳関門通過可能なペプチド結合体 | |
| GB2488023A (en) | Immobilised fibrinogen binding peptides | |
| JP2011507919A5 (enExample) | ||
| US20060127387A1 (en) | Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions | |
| CN101168594B (zh) | 寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物 | |
| US20170349644A1 (en) | Factor viii with extended half-life and reduced ligand-binding properties | |
| JP5798628B2 (ja) | ウシ顆粒球コロニー刺激因子のための製剤およびその変異体 | |
| CN101591387A (zh) | 聚乙二醇化重组人干扰素ω偶合物 | |
| JPH0480008B2 (enExample) | ||
| KR20210031478A (ko) | 고분자 화합물 및 이를 이용한 세포내 화합물 도입 촉진제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131024 |